NICE recommends against Bronchitol for CF

The U.K.'s NICE recommended against Bronchitol mannitol from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) for use in cystic fibrosis patients aged 18 years and older as an add-on therapy to best standard of care, its approved indication. In draft guidance released late Thursday, NICE said there were gaps and uncertainties in the evidence for the drug's effectiveness compared with hypertonic saline, which the committee said is typically used in about 40% of U.K. CF patients following treatment with recombinant human deoxyribonuclease (rhDNase). NICE also questioned the long-term effect of Bronchitol on lung function. ...